Clinical effect of
LM-001, a
prostaglandin synthetic inhibitor developed from a drug delivery system, was evaluated in 54 patients with
pain from
urinary tract stones (stone
pain) and 32 with vesical urgency after an operation on bladder or prostate.
LM-001,
felbinac ethyl incorporated in
lipid microsphere, wes intravenously administered at the onset of stone
pain or vesical urgency. Of 54 with stones and 32 with urgency, 53 and 29 were eligible for response, respectively. The symptoms improved or disappeared in some cases just after the administration and in the majority of patients within 15 minutes, in 49 of 53 patients with stone
pain. Further, the effectiveness lasted over 24 hours in 26 of the 49 responding to this agent. On one hand, improvement or disappearance of vesical urgency was recognized in 25 of 29 patients, and the effectiveness was observed shortly after injection in 16 and lasted over 24 hours in 13 cases. Toxicities of this
drug were investigated in 54 patients with stone
pain and 32 with urinary urgency. Side effects consisted of
pain at the injection site in 4, a slight fall of blood pressure in 1, slight visual disturbance in 1, body heat sensation in 1,
leukocytosis in 3 and elevation of
alkaline phosphatase in 1. These symptoms were transient and disappeared without use of any agent.
LM-001 is concluded to be a useful
drug for controlling stone
pain and vesical urgency since an immediate effect, long durability and high response rates were obtained without severe side